-
公开(公告)号：US09770494B2
公开(公告)日：2017-09-26
申请号：US14318232
申请日：2014-06-27
Applicant: ThromboGenics NV
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
-
公开(公告)号：US09186394B2
公开(公告)日：2015-11-17
申请号：US13827986
申请日：2013-03-14
Applicant: ThromboGenics NV
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
-
公开(公告)号：US20110300123A1
公开(公告)日：2011-12-08
申请号：US13097985
申请日：2011-04-29
Applicant: Steve PAKOLA , Marc DE SMET
Inventor： Steve PAKOLA , Marc DE SMET
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Abstract translation: 治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。 本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物 增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。 该方法可用于玻璃体切除术的缺失或辅助。
-
公开(公告)号：US20150023942A1
公开(公告)日：2015-01-22
申请号：US14317106
申请日：2014-06-27
Applicant: Acorda Therapeutics, Inc.
Inventor： Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sara J. Kasperbauer , Gargi Roy
IPC: A61K38/51
CPC classification number: A61K38/51 , C12N9/88 , C12Y402/02005 , C12Y402/02019
Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
Abstract translation: 通过施用软骨素酶AC和/或软骨素酶B来降解抑制或有助于抑制神经组织再生的硫酸软骨素蛋白聚糖来实现中枢神经系统中的神经生长。
-
公开(公告)号：US08785606B2
公开(公告)日：2014-07-22
申请号：US13451968
申请日：2012-04-20
Applicant: Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sarah J. Kasperbauer , Gargi Roy
Inventor： Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sarah J. Kasperbauer , Gargi Roy
IPC: A61K38/48 , A61K31/726 , A61K31/737
CPC classification number: A61K38/51 , C12N9/88 , C12Y402/02005 , C12Y402/02019
Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
Abstract translation: 通过施用软骨素酶AC和/或软骨素酶B来降解抑制或有助于抑制神经组织再生的硫酸软骨素蛋白聚糖来实现中枢神经系统中的神经生长。
-
Patent Agency Ranking
公开(公告)号：US20130202613A1
公开(公告)日：2013-08-08
申请号：US13690427
申请日：2012-11-30
Applicant: ThromboGenics NV
Inventor： Steve PAKOLA , Marc DE SMET
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
-
公开(公告)号：US07867489B2
公开(公告)日：2011-01-11
申请号：US12156911
申请日：2008-06-05
Applicant: Steve Pakola , Marc De Smet
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Abstract translation: 治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。 本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物 增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。 该方法可用于玻璃体切除术的缺失或辅助。
-
公开(公告)号：US20080050356A1
公开(公告)日：2008-02-28
申请号：US11786250
申请日：2007-04-11
Applicant: Steve Pakola , Marc De Smet
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
-
公开(公告)号：US08383105B2
公开(公告)日：2013-02-26
申请号：US12951787
申请日：2010-11-22
Applicant: Steve Pakola , Marc De Smet
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
-
公开(公告)号：US07547435B2
公开(公告)日：2009-06-16
申请号：US10729475
申请日：2003-12-05
Applicant: Steve Pakola , Marc De Smet
Inventor： Steve Pakola , Marc De Smet
CPC classification number: A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
Abstract: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Abstract translation: 包括使玻璃体和/或房水与包含纤溶酶（TPCD）的催化结构域的截短形式的纤溶酶的组合物接触的方法，所述方法包括使玻璃体和/或房室液体接触， 披露 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。 本发明的方法可用于降低玻璃体的粘度，使玻璃体液化，诱导玻璃体后脱离，减少眼睛出血，清除或减少对眼睛有毒的物质，清除或减少眼内异物 增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。 该方法可用于玻璃体切除术的缺失或辅助。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.018 seconds)
